A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia
Furman RR, Vos SD, Leonard JP, et al.
Key Points:
Results of phase 1 study -- idelalisib plus rituximab or ofatumumab -- reported
Safety data indicated that combinations were safe with acceptable toxicity profiles in relapsed/refractory CLL
Promising anti-tumor activity noted with an ORR of 83% in 40 patients evaluated for response
Implications:
- Combinations may represent novel treatment options in heavily pretreated CLL patients
View the original abstract on the ASH website.
